DrAfter123/Digital Vision Vectors/Getty Images
Like many colleagues, Ohio State oncologist Ning Jin is alarmed by a rising number of patients in their 30s and 40s presenting with late-stage cancers of the lower digestive tract. These patients are decades younger than was once typical, and their tumors often resist standard treatments. “Even though we treat young patients with more aggressive chemo — more chemo or more surgery — patients’ outcomes are not necessarily better,” Jin says. Colorectal cancer has become the top cancer killer among people under 50, even as death rates fall in older groups.
Scientific advances have made many cancers more treatable and survivable, but colorectal cancer is increasingly deadly and strikes people at younger ages and with greater frequency. What’s driving this trend is a major medical mystery. Increasingly, researchers suspect the gut microbiome— the trillions of bacteria and other microorganisms living in our digestive tract—may be a central factor.
Patient advocates stress the importance of diagnostic testing, especially for younger adults with a family history of colorectal cancers. Routine preventive screening is generally recommended and covered by insurance beginning at age 45, so young people should watch for symptoms and discuss concerns with their doctors.
A generational change
Genetics explain some colorectal cancers: Jin says about one in five patients carry hereditary markers such as mutations linked to Lynch syndrome. But genetics do not account for roughly 80% of cases, prompting clinicians to look for environmental or generational shifts.
Dr. John Marshall, head of clinical research at Georgetown’s Lombardi Cancer Center, has observed striking changes across a single generation. “Thirty-plus years ago, when I first started, no one — no one; zero number of patients — were in my clinic under the age of 50 with colon cancer,” he recalls. Now, he sees nearly half of his patients under 50. He and others note additional shifts in tumor patterns: more early-onset cancers are appearing lower in the tract, nearer the rectum. Such rapid change suggests a factor or set of factors linked to modern life.
Potential culprits
Experts point to several possible contributors: greater reliance on ultra-processed foods, exposure to plastics and industrial chemicals that leach into food and water, and increasingly sedentary lifestyles. The prevailing theory ties these influences to changes in the gut’s microbial community. A disturbed microbiome may promote inflammation, weaken barriers, or produce toxins that damage DNA.
Marshall likens the microbiome to soil: “It’s a very important part of our interface with the world,” he says. If that soil is altered—by diet, chemicals, or other exposures—it could help drive colon cancer and possibly other diseases.
Some chemicals may strip away the gut’s protective mucus layer, a partial barrier that keeps harmful agents from contacting the gut lining. Losing that shield is like tearing slats from a fence: it leaves tissue vulnerable to inflammation. Jin explains that microbes or chemicals can cause “leaky gut,” inflammation, and direct DNA damage—processes that can contribute to tumor formation.
Searching deeper
While links between the microbiome and colorectal cancer are increasingly evident, the mechanisms remain complex and hard to isolate. Different regions of the digestive tract—the mouth, stomach, small intestine, and colon—have distinct chemistries and microbial communities, any of which could contribute to cancer development.
One study found an association between colibactin, a DNA-damaging toxin produced by certain E. coli strains and other bacteria, and colon cancers in younger patients, suggesting a direct microbial role. Still, measuring microbiome health is challenging: researchers lack reliable tests to determine whether an individual’s microbiome is “healthy” or how to restore it.
Because multiple environmental exposures and lifestyle changes likely interact with microbes to increase cancer risk, Jin and others say more controlled studies are needed to tease apart which factors trigger carcinogenesis and when interventions might prevent it. Until researchers can identify clear causal pathways and effective tests, clinicians and patients must weigh family history, symptoms, and available screening recommendations while scientists continue probing the gut for answers.